Roche outlined a push to become an end-to-end oncology solutions provider, anchored by acquisitions in cancer diagnostics and expansion of its sequencing and pathology ecosystem. During its Diagnostics Day, the company highlighted pending deals including PathAI for computational pathology and Saga Diagnostics for MRD monitoring capabilities via Pathlight. Roche also positioned its new sequencing instrument, Axelios, as a key platform to support molecular oncology testing across clinical workflows, including companion diagnostic development with pharma partners. Executives said PathAI integrates with Roche’s Ventana tissue pathology business and supports earlier engagement on therapy selection and monitoring. On the monitoring side, Roche’s Foundation Medicine will integrate Pathlight MRD evidence generation and invest further in expanding clinical support across additional indications beyond breast cancer. The company expects Axelios to be an accelerator for growth in molecular testing markets. For biotech and pharma partners, the practical outcome is a tighter integration path from early detection to treatment selection and disease monitoring within a single vendor ecosystem.